--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ZL-1310, a potential highly ...
(RTTNews) - Zai Lab Limited (ZLAB) announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation or ODD to ZL-1310, a potential highly active first-in-class DLL3 ...
The FDA has granted orphan drug designation (ODD) to Zai Lab’s ZL-1310, aimed at treating small cell lung cancer (SCLC).
"Building on the promising findings from our ongoing clinical trials for ZL-1310, this new collaboration demonstrates our continued focus on developing cancer therapies with ADC drugs and enriches ...
Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC) Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the ...
Hosted on MSN14d
FDA grants ODD status to Zai Lab’s lung cancer treatmentThe US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to Zai Lab’s delta-like ligand 3 (DLL3) antibody-drug conjugate (ADC), ZL-1310, for small cell lung cancer (SCLC).
NDAQ:ZLAB) Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell ...
SHANGHAI & CAMBRIDGE, Mass., January 23, 2025--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results